

# Appendix 4E

(Rule 4.3A)

## Preliminary final report

Name of entity

Nanoveu Limited	ABN: 97 624 421 085
-----------------	---------------------

### 1. Details of the Reporting Period and the Previous Corresponding Period

Financial period ended ("current period")	Financial period ended ("previous period")
31 December 2020	31 December 2019

### 2. Results for Announcement to the Market

					2020 \$'000
2.1	Revenue from ordinary activities	up	503%	to	368
2.2	Loss from ordinary activities after tax attributable to members	down	48%	to	1,762
2.3	Net loss for the period attributable to members	down	48%	to	1,762
2.4	Loss per share	down	49%	to	1.3 cents

#### 2.5 Brief explanation of results

<p>Highlights for the year were:</p> <ul style="list-style-type: none"> <li>• Anti-viral protection product for digital screen and surfaces developed into commercial product for large addressable market of smartphone users</li> <li>• Positive independent laboratory test results assessing effectiveness against: <ul style="list-style-type: none"> <li>○ Influenza A virus subtype H3N2<sup>1</sup></li> <li>○ Feline calicivirus strain F9 (Norovirus surrogate)<sup>2</sup></li> <li>○ E.coli<sup>3</sup></li> <li>○ Staphylococcus aureus<sup>4</sup></li> <li>○ MHV-A59 coronavirus (a surrogate of human coronavirus 229E)5OC43 (human transmitted coronavirus strain)<sup>6</sup></li> <li>○ MS2 Bacteriophage, a single-strand RNA virus<sup>7</sup></li> </ul> </li> </ul>
--

<sup>1</sup> See ASX Announcement dated 15 April 2020

<sup>2</sup> See ASX Announcement dated 15 April 2020

<sup>3</sup> See ASX Announcement dated 15 April 2020

<sup>4</sup> See ASX Announcement dated 15 April 2020

<sup>5</sup> See ASX Announcement dated 5 May 2020

<sup>6</sup> See ASX Announcement dated 25 May 2020

<sup>7</sup> See ASX Announcement dated 18 February 2021

<ul style="list-style-type: none"> <li>• Antiviral product registered with TGA as a class-one medical device<sup>8</sup></li> <li>• Executed distribution agreements for Australia, New Zealand, Malaysia, Singapore, Thailand and the UK;</li> <li>• Launched commercial product with first sales generated in Q3 2020,</li> <li>• Key milestone for the EyeFyx vision correction project achieved with the development of a working prototype for computers and patents filed; and</li> <li>• Additional funding secured via an equity placement facility of up to \$2,400,000 of which \$600,000 was received during the year and a private placement raising \$660,000.</li> </ul> <p>For further details, please refer to the financial report.</p>
--

### 3. NTA Backing

	Current period	Previous corresponding period
Net tangible asset backing per ordinary security	\$0.008	\$0.015

### 4 Control gained or lost over entities having material effect

n/a

### 5. Dividends

There were no dividends declared or paid during the period and the do not recommend that any dividends be paid.

### 6. Dividend Reinvestment Plans

Not applicable.

### 7. Material interest in entities which are not controlled entities

Not applicable.

### 8. Foreign Entities

This report includes the following foreign subsidiaries:

- Nanoveu Pte Ltd, registered in Singapore; and
- Nanoveu Distribution Inc., registered in the United States of America.

### 9. Annual Report

Refer to the attached Annual Report for the year ended 31 December 2020 for further details. The financial statements contained in the annual report have been audited.

This report should be read in conjunction with the attached Annual Report for the year ended 31 December 2020.

<sup>8</sup> See ASX Announcement dated 2 June 2020

For personal use only

For personal use only

Signed by:



Date: 25<sup>th</sup> February 2021

Name:

Alfred Chong  
CEO & Executive Chairman